Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis

Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent Phase 2 study (NCT03099187) described a significant effect of pirfenidone vs. placebo on forced vital capacity (FVC) measured by site spirom...

Full description

Bibliographic Details
Main Authors: Maria Molina-Molina, Michael Kreuter, Vincent Cottin, Tamera J. Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M. Maher
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Medicine
Subjects:
lung function
pirfenidone
post-hoc analysis
surgical lung biopsy
unclassifiable interstitial lung disease
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.897102/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.897102/full

Similar Items